logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5632.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5632.produseast1
Showing 1 - 20 of 71 Items
Showing 1 - 20 of 71 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Pre-Print

Effect of smoking on drug-resistant tuberculosis treatment outcomes and exploring potential pathways: A multicountry cohort study

Romo ML, LaHood A, Stagg HR, Mitnick CD, Trevisi L,  et al.
2025-08-24 • medRxiv
2025-08-24 • medRxiv

People who smoke are at increased risk of unfavorable tuberculosis (TB) treatment outcomes compared with tho...

Journal Article
|
Research

Characterizing treatment adherence trajectories in the endTB multisite cohort of drug-resistant tuberculosis patients: an application of group-based trajectory modelling

Law S, Fulcher I, Ashraf S, Bastard M, Docteur W,  et al.
2025-08-22 • Clinical Infectious Diseases
2025-08-22 • Clinical Infectious Diseases

BACKGROUND

In tuberculosis (TB) care, adherence is often assessed using a simple 80% threshold, ...

Journal Article
|
Research

The frequency and incidence of QT prolongation with extended use of bedaquiline or delamanid in a large, multi-country multidrug-resistant/rifampicin-resistant tuberculosis cohort

Khan U, Rich M, Franke MF, Lachenal N, Ahmed S,  et al.
2025-08-01 • Clinical Infectious Diseases
2025-08-01 • Clinical Infectious Diseases

BACKGROUND

The 2022 World Health Organization (WHO) guidelines on multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) recommend 6 months of bedaqu...

Journal Article
|
Research

COVID-19, tuberculosis, and HIV triad: a prospective observational study in ambulatory patients in Kenya, Uganda, and South Africa

Huerga H, Gouillou M, Ohler L, Taremwa IM, Akinyi M,  et al.
2025-04-23 • PLOS Global Public Health
2025-04-23 • PLOS Global Public Health

People living with HIV (PLHIV) have an increased risk of tuberculosis (TB) and severe COVID-19. TB and COVI...

Journal Article
|
Research

Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis—experiences from Armenia

Ardizzoni E, Mulders W, De Diego Fuertes M, Hayrapetyan A, Mirzoyan A,  et al.
2025-04-09 • Antimicrobial Agents and Chemotherapy
2025-04-09 • Antimicrobial Agents and Chemotherapy

Risk factors for baseline bedaquiline (BDQ) resistance, amplification during treatment, and correlations with treatment outcomes are not fully understood. This cohort included Armenia...

Journal Article
|
Research

The frequency and incidence of QT prolongation with extended use of bedaquiline or delamanid in a large, multi-country MDR/RR-TB cohort

Khan U, Rich M, Franke M, Lachenal N, Ahmed S,  et al.
2024-12-10 • Clinical Infectious Diseases
2024-12-10 • Clinical Infectious Diseases

BACKGROUND

The 2022 WHO guidelines on multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) recommend six months of bedaquiline (Bdq) in the all-oral 9-month shorter regimen ...

Conference Material
|
Abstract

Treatment of children and adolescents with MDR/RR-TB regimens containing bédaquiline and delamanid: results from the endTB observational study

Bastard M
2024-05-23 • Epicentre Scientific Day 2024
2024-05-23 • Epicentre Scientific Day 2024
BACKGROUND
Children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB) are under diagnosed and under treated. Few reports exist on the treatme...
Journal Article
|
Research

Sputum culture reversion in longer treatments with bedaquiline, delamanid, and repurposed drugs for drug-resistant tuberculosis

Kho S, Seung KJ, Huerga H, Bastard M, Khan PY,  et al.
2024-05-09 • Nature Communications
2024-05-09 • Nature Communications
Sputum culture reversion after conversion is an indicator of tuberculosis (TB) treatment failure. We analyze data from the endTB multi-country prospective observational cohort (NCT032592...
Journal Article
|
Research

Case fatality risk among individuals vaccinated with rVSVΔG-ZEBOV-GP: a retrospective cohort analysis of patients with confirmed Ebola virus disease in the Democratic Republic of the Congo

Coulborn RM, Bastard M, Peyraud N, Gignoux EM, Luquero FJ,  et al.
2024-02-01 • Lancet Infectious Diseases
2024-02-01 • Lancet Infectious Diseases
BACKGROUND
The rVSVΔG-ZEBOV-GP vaccine constitutes a valuable tool to control Ebola virus disease outbreaks. This retrospective cohort study aimed to assess the protective effect of ...
Journal Article
|
Research

Estimating post-treatment recurrence after multidrug-resistant tuberculosis treatment among patients with and without HIV: the impact of assumptions about death and missing follow-up

Sauer SM, Mitnick CD, Khan UT, Hewison CCH, Bastard M,  et al.
2024-01-25 • Clinical Infectious Diseases
2024-01-25 • Clinical Infectious Diseases
BACKGROUND
Quantification of recurrence risk following successful treatment is crucial to evaluating regimens for multidrug- or rifampicin-resistant (MDR/RR) tuberculosis (TB). Howev...
Journal Article
|
Research

Effectiveness of a bedaquiline, linezolid, clofazimine “core” for multidrug-resistant tuberculosis

Zeng C, Hernán MA, Trevisi L, Sauer S, Mitnick CD,  et al.
2024-01-20 • medRxiv
2024-01-20 • medRxiv

RATIONALE

Treatment outcomes may be compromised among patients with multidrug- or rifampicin-resistant tuberculosis with additional fluoroquinolone resis...

Journal Article
|
Research

Factors associated with adverse outcomes among patients hospitalized at a COVID-19 treatment center in Herat, Afghanistan

Klein A, Bastard M, Hemat H, Singh SN, Muniz B,  et al.
2023-08-24 • PLOS Global Public Health
2023-08-24 • PLOS Global Public Health
Though many studies on COVID have been published to date, data on COVID-19 epidemiology, symptoms, risk factors and severity in low- and middle-income countries (LMICS), such as Afghanis...
Journal Article
|
Research

Effectiveness of bedaquiline use beyond six months in patients with multidrug-resistant tuberculosis

Trevisi L, Hernán MA, Mitnick CD, Khan UT, Seung KJ,  et al.
2023-06-01 • American Journal of Respiratory and Critical Care Medicine
2023-06-01 • American Journal of Respiratory and Critical Care Medicine
RATIONALE
Current recommendations for the treatment of rifampin- and multidrug-resistant tuberculosis include bedaquiline used for six months or longer. Evidence is needed to inform ...
Journal Article
|
Research

Outcomes of WHO-conforming, longer, all-oral multidrug-resistant TB regimens and analysis implications

Rich ML, Khan UT, Zeng C, LaHood AN, Franke MF,  et al.
2023-06-01 • International Journal of Tuberculosis and Lung Disease
2023-06-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
Evidence of the effectiveness of the WHO-recommended design of longer individualized regimens for multidrug- or rifampicin-resistant TB (MDR/RR-TB) is limited.

OB...
Journal Article
|
Research

Diagnostic yield of urine lipoarabinomannan and sputum tuberculosis tests in people living with HIV: a systematic review and meta-analysis of individual participant data

Broger T, Koeppel L, Huerga H, Miller P, Gupta-Wright A,  et al.
2023-06-01 • Lancet Global Health
2023-06-01 • Lancet Global Health
BACKGROUND
Sputum is the most widely used sample to diagnose active tuberculosis, but many people living with HIV are unable to produce sputum. Urine, in contrast, is readily availab...
Journal Article
|
Research

Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effective

Rodriguez CA, Lodi S, Horsburgh CR, Mitnick CD, Bastard M,  et al.
2023-04-28 • PLOS Global Public Health
2023-04-28 • PLOS Global Public Health
Clarity about the role of delamanid in longer regimens for multidrug-resistant TB is needed after discordant Phase IIb and Phase III randomized controlled trial results. The Phase IIb tr...
Journal Article
|
Pre-Print

Factors associated with adverse outcomes among patients hospitalized at a COVID-19 treatment center run by Médecins sans Frontières in Herat, Afghanistan

Klein A, Bastard M, Hemat H, Singh SN, Muniz B,  et al.
2023-02-16 • medRxiv
2023-02-16 • medRxiv
BACKGROUND
Though many studies on COVID have been published to date, data on COVID-19 epidemiology, symptoms, risk factors and severity in low- and middle-income countries (LMICS), s...
Journal Article
|
Research

Effect of large-scale mass drug administration for malaria on mortality and morbidity in Angumu health zone, Ituri, Democratic Republic of Congo

Grout L, Katuala Givo Y, Newport T, Mahamat TA, Gitahi P,  et al.
2023-02-06 • Malaria Journal
2023-02-06 • Malaria Journal
BACKGROUND
Angumu health zone in Ituri, Democratic Republic of Congo, is a highly malaria-endemic area with an overburdened health system and hosting internally displaced persons (ID...
Journal Article
|
Research

Concordance of three approaches for operationalizing outcome definitions for multidrug-resistant TB

Zeng C, Mitnick CD, Hewison CCH, Bastard M, Khan PY,  et al.
2023-01-01 • International Journal of Tuberculosis and Lung Disease
2023-01-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
The WHO provides standardized outcome definitions for rifampicin-resistant (RR) and multidrug-resistant (MDR) TB. However, operationalizing these definitions can be challe...
Journal Article
|
Research

Novel FujiLAM assay to detect tuberculosis in HIV-positive ambulatory patients in four African countries: a diagnostic accuracy study

Huerga H, Bastard M, Lubega AV, Akinyi M, Antabak NT,  et al.
2023-01-01 • Lancet Global Health
2023-01-01 • Lancet Global Health
BACKGROUND
Development of rapid biomarker-based tests that can diagnose tuberculosis using non-sputum samples is a priority for tuberculosis control. We aimed to compare the diagnost...